Clinical data | |
---|---|
Other names | TS-1211 |
Routes of administration | By mouth |
TS-121 (THY1773) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder. [1] [2] [3] As of May 2017, it is in phase II clinical trials for this indication. [1] [2] [4]
Clinical data | |
---|---|
Other names | TS-1211 |
Routes of administration | By mouth |
TS-121 (THY1773) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder. [1] [2] [3] As of May 2017, it is in phase II clinical trials for this indication. [1] [2] [4]